PBHNYSEPharmaceutical PreparationsFiscal year ends March 31
Prestige Consumer Healthcare Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$49.71−0.21 (-0.42%)
Close on Oct 19, 2026
- Market cap
- $2.37B
- P/E (TTM)
- 13.9
- Dividend yield
- –
Prestige Consumer Healthcare Inc. revenue by segment
By business segment
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North American OTC Healthcare | $927.20M | $913.58M | $927.98M | $931.22M | $940.27M | $960.01M | $942.19M | $939.82M | $944.43M | $958.26M | $969.45M | $969.77M | 83.9% | -1.4% |
| International OTC Healthcare | $177.68M | $175.13M | $175.63M | $179.26M | $179.88M | $177.75M | $176.05M | $170.84M | $168.76M | $167.10M | $164.79M | $157.25M | 16.1% | -1.2% |
By product or service
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | $1.10B | $1.08B | $1.10B | $1.11B | $1.12B | $1.14B | $1.12B | $1.11B | $1.11B | $1.13B | $1.13B | $1.13B | 99.2% | -2.1% |
| Gastrointestinal | $264.21M | $259.79M | $260.32M | $259.85M | $255.71M | $255.94M | $246.70M | $239.33M | $232.03M | $231.61M | $230.41M | $225.54M | 23.9% | +3.3% |
| Women's Health | $223.55M | $227.77M | $232.32M | $232.68M | $236.83M | $236.83M | $233.22M | $233.36M | $235.09M | $240.42M | $243.37M | $243.16M | 20.2% | -5.6% |
| Eye & Ear Care | $143.61M | $142.94M | $151.81M | $158.89M | $167.50M | $183.32M | $180.58M | $179.98M | $184.06M | $179.42M | $182.59M | $175.40M | 13.0% | -14.3% |
| Dermatologicals | $129.02M | $125.93M | $124.53M | $125.54M | $125.70M | $128.95M | $130.70M | $127.81M | $126.44M | $129.10M | $129.58M | $130.01M | 11.7% | +2.6% |
| Oral Care | $101.71M | $101.05M | $100.15M | $96.64M | $95.96M | $95.03M | $93.25M | $93.63M | $92.33M | $96.31M | $96.03M | $96.68M | 9.2% | +6.0% |
| Other revenues | $9.08M | $3.96M | $1.33M | $1.24M | $1.13M | $1.18M | $1.13M | $836.00K | $608.00K | $311.00K | $79.00K | $82.00K | 0.8% | +706.7% |
| Cough & Cold | – | $101.91M | $102.53M | $102.53M | $104.52M | $106.21M | $105.49M | $109.33M | $113.29M | $119.02M | $123.15M | $127.56M | – | – |
| Analgesics | – | $113.94M | $115.90M | $118.85M | $118.34M | $117.70M | $115.30M | $114.58M | $117.72M | $117.45M | $117.33M | $117.11M | – | – |
| Other OTC | – | $15.39M | $13.88M | $13.31M | $13.41M | $13.78M | $13.00M | $12.63M | $12.22M | $12.03M | $11.78M | $11.57M | – | – |
By region
From the segment and revenue-disaggregation notes of Prestige Consumer Healthcare's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.